Showing results (1-10 of 60) with videos related to
Sort By:
Pageof 6
Diabetes & Metabolic Syndrome|March 26, 2014
India suspends pioglitazone: is it justified?S M Sadikot, Samit GhosalDiabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 16, 2019
Sodium-Glucose Cotransporter-2 Inhibitors (SGLT-2i) Reduce Hospitalization for Heart Failure Only and Have No Effect on Atherosclerotic Cardiovascular Events: A Meta-AnalysisBinayak Sinha, Samit GhosalDiabetes & Metabolic Syndrome|December 4, 2014
Hypoglycaemia and CV risk: Perceptions and realitySamit Ghosal, Binayak SinhaAddiction Science & Clinical Practice|December 5, 2025
The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: a systematic review and meta-analysisBinayak Sinha, Samit GhosalCurrent Diabetes Reviews|October 26, 2019
Is it Worth CANVASing for CREDENCE? A Benefit-risk AnalysisBinayak Sinha, Samit GhosalDiabetes, Metabolic Syndrome and Obesity : Targets and Therapy|December 2, 2025
Optimising GLP-1RA Efficacy: A Meta-Analysis of Baseline Age and HbA1c as Predictors of MACE Reduction in T2DMSamit Ghosal, Anuradha GhosalInternational Journal of Hepatology|January 16, 2026
Global Bivariate Meta-Analysis of FIB-4 Cut-Offs to Rule Out Advanced Fibrosis in MASLDAnuradha Ghosal, Samit GhosalDiabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|November 7, 2025
Risk-Benefit Trade-offs of GLP-1RAs and SGLT-2is in Type 2 Diabetes Mellitus (T2D): Systematic Review, Meta-Analysis, and Net Benefit ModelingSamit Ghosal, Anuradha GhosalFrontiers in Endocrinology|July 20, 2023
Exploring the comparative cardiovascular death benefits of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a frequentist and Bayesian network meta-analysis-based scoringSamit Ghosal, Binayak SinhaCurrent Diabetes Reviews|February 7, 2020
Redefining Cardiovascular (CV) Death as a Primary Endpoint Component in Cardiovascular Outcome TrialsSamit Ghosal, Binayak SinhaPageof 6